Ultrasound therapy probe
Abstract
Abstract Translated from Japanese (57)【要約】 (修正有) 【課題】 超音波ビームの照射により音波振動子側の蛋 白質変性組織に妨げられることなく、病変部が焼灼でき たか否かを確認できる超音波治療用プローブを提供す る。 【解決手段】 硬質の挿入管20の先端付近には集束点 31で超音波ビームが集束するように送出する治療用超 音波振動子21を内蔵し、その先端側には湾曲自在の湾 曲部19を形成し、更にその先端側には観測用超音波振 動子17を設けた硬質の先端部18が形成さる。湾曲部 19を上方向に湾曲させた場合、振動子17の超音波観 測領域46を含む平面に振動子21による集束点31が 含まれ、湾曲角の値の変化により、集束点付近を超音波 ビームの送出方向と異なる任意の方向から観察できるよ うにして、超音波ビームの照射により集束点より振動子 21側の組織が蛋白質変性して減衰が大きくなった場合 にも、その組織に妨げられることなく、集束点付近の病 変部が焼灼できたか否かを観測画像で確認可能にした。 (57) [Abstract] (Modified) [PROBLEMS] To provide an ultrasonic therapeutic probe capable of confirming whether or not a lesion has been cauterized without being disturbed by the protein-denatured tissue on the side of the acoustic wave oscillator by irradiation of the ultrasonic beam. provide. SOLUTION: A therapeutic ultrasonic transducer 21 for transmitting an ultrasonic beam so as to focus it at a focusing point 31 is built in near the tip of a rigid insertion tube 20, and a bendable bending portion 19 is provided on the tip side thereof. And a hard tip portion 18 provided with an ultrasonic transducer 17 for observation is formed on the tip side thereof. When the bending portion 19 is bent upward, the focusing point 31 by the transducer 21 is included in the plane including the ultrasonic observation region 46 of the transducer 17, and the ultrasonic wave is generated near the focusing point due to the change in the bending angle value. Even when the tissue on the oscillator 21 side of the focusing point is denatured by the irradiation of the ultrasonic beam and the attenuation is increased by observing from an arbitrary direction different from the beam sending direction, the tissue is obstructed by the tissue. It was possible to confirm whether or not the lesion near the focal point was cauterized without any observation.
Inventors
- 👤 Sayuri Kamiya
- 👤 さゆり 神谷
Bibliographic Details
Claims Analysis
Total Claims: 0References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.